1.Donnan GA, Fisher M, Macleod M, et al. Stroke. Lancet. 2008;371:1612–23.
2.Feigin VL. Stroke epidemiology in the developing world. Lancet. 2005;365:2160–1.
3.Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in china: Results from a nationwide population-based survey of 480687 adults. Circulation. 2017;135:759–71.
4.Miao Y, Liao JK. Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother. 2014;14:173–85.
5.Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.
6.Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043–6.
7.Sedlak TW, Saleh M, Higginson DS, et al. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA. 2009;106:5171–6.
8.Syapin PJ. Regulation of haeme oxygenase–1 for treatment of neuroinflammation and brain disorders. Br J Pharmacol. 2008;155:623–40.
9.Kundur AR, Singh I, Bulmer AC. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert’s syndrome? Atherosclerosis. 2015;239:73–84.
10.Ekblom K, Marklund SL, Johansson L, et al. Bilirubin and UGT1A1*28 Are Not Associated with Lower Risk for Ischemic Stroke in a Prospective Nested Case-Referent Setting. Cerebrovasc Dis. 2010;30:590–6.
11.Kunutsor SK, Bakker SJ, Gansevoort RT, et al. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35:716–24.
12.Lee SJ, Jee YH, Jung KJ, et al. Bilirubin and Stroke Risk Using a Mendelian Randomization Design. Stroke. 2017;48:1154–60.
13.Oda E, Kawai R. A possible cross-sectional association of serum total bilirubin with coronary heart disease and stroke in a Japanese health screening population. Heart Vessels. 2012;27:29–36.
14.Jørgensen ME, Torp-Pedersen C, Finer N, et al. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. Nutr Metab Cardiovasc Dis. 2014;24:656–62.
15.Zhou X, Wang L, Liu H, et al. Serum antioxidant levels associated with subcortical ischemic vascular disease. Can J Neurol Sci. 2014;41:375–81.
16.Kim J, Yoon SJ, Woo MH, et al. Differential impact of serum total bilirubin level on cerebral atherosclerosis and cerebral small vessel disease. PloS One. 2017;12:e0173736.
17.Schooling CM, Kelvin EA, Jones HE. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Ann Epidemiol. 2012;22:789–98.
18.Temme EH, Zhang J, Schouten EG, et al. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control. 2001;12:887–94.
19.Kimm H, Yun JE, Jo J, et al. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke. 2009;40:3422–7.
20.Perlstein TS, Pande RL, Creager MA, et al. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999–2004. Am J Med. 2008;121:781–8.
21. Zhong P, Wu DH, Ye XF, et al. Association of circulating total bilirubin level with ischemic stroke: a systemic review and meta-analysis of observational evidence. Ann of Transl Med. 2019;7:335.
22.Franchini M, Targher G, Lippi G. Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? Adv Clin Chem. 2010;50:47–63.
23.Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007;43:1–57.
24.Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.
25.Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283;2008–12.
26.Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
27.Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301–9.
28.Royston P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med. 2000;19:1831–47.
29.Bagnardi V, Zambon A, Quatto P, et al. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol. 2004;159:1077–86.
30.Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
31.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
32.Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem. 2010;56:1535–43.
33.Erdogan D, Gullu H, Yildirim E, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis. 2006;184:431–7.
34.Balta S, Balta I, Mikhailidis DP, et al. Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Am J Clin Dermatol. 2014;15:137–42.
35.Kawamoto R, Ninomiya D, Hasegawa Y, et al. Mildly Elevated Serum Bilirubin Levels Are Negatively Associated with Carotid Atherosclerosis among Elderly Persons. PLoS One. 2014;9:e114281.
36.Dullaart RP, Kappelle PJ, de Vries R. Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and Type 2 diabetic subjects. Clin Chim Acta. 2012;414:161–5.
37.Vitek L, Novotný L, Sperl M, et al. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis. 2006;21:408–14.
38.Wagner KH, Wallner M, Mölzer C, et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (London). 2015;129:1–25.
39.McCarty MF. '‘Iatrogenic Gilbert syndrome’‘—a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med hypotheses. 2007;69:974–94.
40.Peterson SJ, Frishman WH, Abraham NG. Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev. 2009;17:99–111.
41.Targher G. Risk of ischemic stroke and decreased serum bilirubin levels: is there a causal link? Arterioscler Thromb Vasc Biol. 2014;34:702–4.
42.Claridge LC, Armstrong MJ, Booth C, et al. Gilbert’s syndrome. BMJ. 2011;342:d2293.
43.Schwertner HA, Vítek L. Gilbert syndrome, UGT1A1*28 allele,and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198:1–11.
44.Vítek L, Jirsa M, Brodanová M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160:449–56.
45.Lin SP, Lin PY, Jiang HL, et al. Is serum total bilirubin useful to differentiate cardioembolic stroke from other stroke subtypes? Neurol Res. 2015;37:727–31.
46.Jr Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
47.Li RY, Cao ZG, Zhang JR, et al. Decreased serum bilirubin is associated with silent cerebral infarction. Arterioscler Thromb Vasc Biol. 2014;34:946–51.
48.Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293–4.
49.van der A Dl, Peeters PH, Grobbee DE, et al. Dietary haem iron and coronary heart disease in women. Eur Heart J. 2005;26:257–62.
50.Kawamura K, Ishikawa K, Wada Y, et al. Bilirubin from heme oxygenase–1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2005;25:155–60.